FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 08 2020 - 6:00AM
FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of
America Securities 2020 Health Care Conference that is being held
virtually on May 12-14, 2020. Enrique Conterno, Chief Executive
Officer, will participate in a fireside chat at 11:00 AM Eastern
Time on Thursday, May 14. A live audio webcast will be available on
the “Events & Presentations” section of the FibroGen website at
www.fibrogen.com. A replay of the fireside chat will be available
for 30 days.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines to treat unmet needs. The Company is
currently developing and commercializing roxadustat, an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, for anemia
associated with chronic kidney disease (CKD). Roxadustat is also in
clinical development for anemia associated with myelodysplastic
syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab,
an anti-CTGF human monoclonal antibody, is in clinical development
for the treatment of idiopathic pulmonary fibrosis (IPF), locally
advanced unresectable pancreatic cancer, and Duchenne muscular
dystrophy (DMD). For more information, please visit
www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino
1.703.474.4452sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D. Corporate
Strategy / Investor Relations 1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2024 to May 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From May 2023 to May 2024